China Pharma Holdings (CPHI) Cash from Operations Growth (3y) (2013 - 2026)
China Pharma Holdings (CPHI) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 8.25% |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 52.97% |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 5.90% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 43.42% |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | -10.08% |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | -8.76% |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 65.60% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | China Pharma Holdings | 41.38 Mn | 41.08 Mn | 83,566.00 | 46.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 66.48% |
| Dec 31, 2025 | -36.18% |
| Sep 30, 2025 | -45.52% |
| Jun 30, 2025 | 42.92% |
| Mar 31, 2025 | 56.24% |
| Dec 31, 2024 | 51.95% |
| Sep 30, 2024 | 52.95% |
| Jun 30, 2024 | -28.21% |
| Mar 31, 2024 | -28.32% |
| Dec 31, 2023 | -27.38% |
| Sep 30, 2023 | 86.52% |
| Jun 30, 2023 | -63.46% |
| Mar 31, 2023 | -81.85% |
| Dec 31, 2022 | 205.28% |
| Sep 30, 2022 | -23.01% |
| Jun 30, 2022 | -42.00% |
| Mar 31, 2022 | -54.93% |
| Dec 31, 2021 | -30.58% |
| Sep 30, 2021 | -35.91% |
| Jun 30, 2021 | 54.57% |